0001104659-24-022575.txt : 20240213 0001104659-24-022575.hdr.sgml : 20240213 20240213214839 ACCESSION NUMBER: 0001104659-24-022575 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240209 FILED AS OF DATE: 20240213 DATE AS OF CHANGE: 20240213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rondoni John CENTRAL INDEX KEY: 0001932219 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38468 FILM NUMBER: 24631666 MAIL ADDRESS: STREET 1: C/O INSPIRE MEDICAL SYSTEMS, INC. STREET 2: 9700 63RD AVENUE NORTH, SUITE 200 CITY: MAPLE GROVE STATE: MN ZIP: 55369 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inspire Medical Systems, Inc. CENTRAL INDEX KEY: 0001609550 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 261377674 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5500 WAYZATA BLVD STREET 2: SUITE 1600 CITY: GOLDEN VALLEY STATE: MN ZIP: 55416 BUSINESS PHONE: 763-957-5037 MAIL ADDRESS: STREET 1: 5500 WAYZATA BLVD STREET 2: SUITE 1600 CITY: GOLDEN VALLEY STATE: MN ZIP: 55416 4 1 tm245999-7_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2024-02-09 0 0001609550 Inspire Medical Systems, Inc. INSP 0001932219 Rondoni John C/O INSPIRE MEDICAL SYSTEMS, INC. 5500 WAYZATA BLVD., SUITE 1600 GOLDEN VALLEY MN 55416 0 1 0 0 Chief Technology Officer 0 Common Stock 2024-02-09 4 A 0 2694 0.00 A 16262 D Employee Stock Option (Right to Buy) 194.87 2024-02-09 4 A 0 4376 0.00 A 2034-02-09 Common Stock 4376 4376 D Represents an award of restricted stock units, which vests in three equal annual installments commencing on February 9, 2025. Each restricted stock unit represents acontingent right to receive one share of Issuer's common stock, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. Includes (i) 58 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan (the "Plan") on June 30, 2023 and (ii) 32 shares acquired under the Plan onDecember 31, 2023. The option vests and becomes exercisable as to 25% of the underlying shares on February 9, 2025. The remaining 75% of the underlying shares will vest and becomeexercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous employment with the Issuer through the relevant vesting dates. /s/ Bryan Phillips, Attorney-in-Fact for John Rondoni 2024-02-13